Clinical trial to evaluate Pholiota adiposa intake on serum glucose level after glucose load in healthy human.

Clinical trial to evaluate Pholiota adiposa intake on serum glucose level after glucose load in healthy human. - Clinical trial with Pholiota adiposa

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035226

Enrollment

Registered

2018-12-12

Start date

2017-10-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy person

Interventions

Cooked Pholiota adipose, 25 g/meal, 50 g/meal, Once a day Placebo containing the three major nutrients 25 g/meal, 50 g/meal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Non smokers (2) Persons who will generally be judged as healthy (3) Persons who have never suffered from asthma (4) Persons who have never developed any allegic reaction to medicines, foods, or other substances. (5) Persons who will give written informed consent by theirselves

Exclusion criteria

Exclusion criteria: 1) Persons who have any dietary supplements, quasi drugs or medicines which cause same or similar efficacy with the effect evaluated in this study. (2) Persons who changed their habitats of supplements within 4 weeks. (3) Persons who work in night shift or in day and night shift. (4) Persons who have been treated their illness or prevention in a clinic at their informed consent persons with their medical histories as follows: serious diseases of Sugar metabolism,lipid metabolismliver function, renal function, heart, circulatory, respiratory, endocrine system, immune system, or mental illness of the nervous system. (6) Persons with the medical histories of alcoholism or drug dependence. (7) Prsons who might be developed allergic reaction to foods. (8) Persons who are pregnant, breast-feeding, or hope to be pregnant during the study period. (9) Persons who had always participated in or will participate in any other clinical trial (to use foods/medicine/quasi medicine/medical device) (10) Persons who will not be judged suitable to the participants by the investigator.

Design outcomes

Primary

Measure	Time frame
glucose level (at min-0, min-30, min-60 and min-120)	—

Secondary

Measure	Time frame
AUC of glucose level	—

Countries

Japan

Contacts

Public ContactKoichiro Ohnuki

Kindai University Department of Biological & Environmental

ohnuki@fuk.kindai.ac.jp0948-22-5655

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026